Kevin Richard Haas
Known title: Chief Technology OfficerCIK: 0001843872
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis. An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.
Transaction History
| VCYT | ▲ Buy | Grant | 44,221 | $0 | 4/10/2026 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 3,355 | $16K | 3/15/2026 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 8,382 | $39K | 3/15/2026 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 4,161 | $19K | 3/14/2026 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 6,412 | $30K | 3/13/2026 | View on chart |
| MYGN | ▲ Buy | Grant | 23,697 | $0 | 2/2/2026 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 1,177 | $12K | 3/24/2025 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 1,724 | $17K | 3/24/2025 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 1,694 | $17K | 3/22/2025 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 4,493 | $45K | 3/22/2025 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 3,335 | $34K | 3/15/2025 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 4,390 | $44K | 3/14/2025 | View on chart |
| MYGN | ▲ Buy | Grant | 54,124 | $0 | 3/13/2025 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 1,016 | $12K | 2/25/2025 | View on chart |
| MYGN | ▲ Buy | Grant | 12,758 | $0 | 2/7/2025 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 2,515 | $61K | 10/9/2024 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 1,172 | $26K | 3/24/2024 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 1,718 | $38K | 3/24/2024 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 1,685 | $37K | 3/22/2024 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 3,306 | $70K | 3/15/2024 | View on chart |
| MYGN | ▲ Buy | Grant | 35,178 | $0 | 3/14/2024 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 881 | $20K | 2/25/2024 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 1,710 | $26K | 10/9/2023 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 858 | $14K | 9/26/2023 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 1,142 | $27K | 3/24/2023 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 1,674 | $40K | 3/24/2023 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 1,677 | $38K | 3/22/2023 | View on chart |
| MYGN | ▲ Buy | Grant | 28,459 | $0 | 3/15/2023 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 1,012 | $19K | 2/25/2023 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 1,721 | $34K | 10/9/2022 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 862 | $16K | 9/26/2022 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 346 | $6K | 9/25/2022 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 1,153 | $29K | 3/24/2022 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 1,689 | $43K | 3/24/2022 | View on chart |
| MYGN | ▲ Buy | Grant | 19,238 | $0 | 3/22/2022 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 865 | $21K | 2/25/2022 | View on chart |
| MYGN | ▲ Buy | Grant | 19,520 | $0 | 2/16/2022 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 1,729 | $53K | 10/9/2021 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 865 | $29K | 9/26/2021 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 346 | $12K | 9/25/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise
Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise. Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.